← All trials
NCT04387773
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Mar 31, 2021
- First posted
- May 14, 2020
- Last posted
- May 14, 2020
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Oregon Health and Science UniversityOverall official - principal investigator
- Oregon Health and Science UniversityReponsible party - principal investigator
- Adamas Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.